The Roche Venture Fund joins international investor syndicate, including co-lead investors Sofinnova Partners and AbbVie Ventures Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company […]
/wp-content/uploads/2019/10/logo_enthera.svg00hearten/wp-content/uploads/2019/10/logo_enthera.svghearten2021-01-28 09:00:522021-01-28 09:24:12Enthera Pharmaceuticals extends Series A financing, raising a total of €35 million
Milan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.
/wp-content/uploads/2019/10/logo_enthera.svg00hearten/wp-content/uploads/2019/10/logo_enthera.svghearten2020-12-03 08:00:022020-12-03 08:44:30Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board to push forward company growth and development
Milan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
/wp-content/uploads/2019/10/logo_enthera.svg00hearten/wp-content/uploads/2019/10/logo_enthera.svghearten2020-07-28 09:00:032020-07-28 11:35:02Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
Enthera Pharmaceuticals extends Series A financing, raising a total of €35 million
/in Press Releases /by heartenThe Roche Venture Fund joins international investor syndicate, including co-lead investors Sofinnova Partners and AbbVie Ventures Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company […]
Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board to push forward company growth and development
/in Press Releases /by heartenMilan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.
Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
/in Press Releases /by heartenMilan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.